

Molecular Therapeutics of Cancer Research Conference -- 2011

Sponsored by the Cancer Molecular Therapeutics Research Association

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

NOTE: ALL SCIENTIFIC SESSIONS, POSTERS AND SOCIALS WILL BE HELD IN THE "CHAPEL."
Lodging will be throughout the Asilomar campus. All meals will be served in the Crocker Dining Hall

SUNDAY – JULY 10

3:00 pm	Arrival and check-in
6:00 – 7:30 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, President CMTRA Sara Courtneidge, Program Chair
7:45 – 10:00 pm	EVENING SESSION: "Tumor cell metabolism and autophagy" Discussion Leader: Eileen White, CINJ, Rutgers University
7.45 – 8:00 pm	Introduction & Overview
8:00 – 8.40 pm	Matt Vander Heiden, MIT "Targeting cancer metabolism: lessons from studies of PKM2 regulation"
8:40 – 9:00 pm	Discussion
9:00 – 9:40 pm	Kun-Liang Guan, UCSD "Mechanism of AMPK and mTORC1 in autophagy regulation"
9:40 – 10:00 pm	Discussion
10:00 pm –	<i>Social</i>

MONDAY – JULY 11

7:30 – 8:15 am	<i>Breakfast</i>
8:15 – 12:00 pm	MORNING SESSION: "Trials and tribulations of combining novel agents" Discussion Leader: Janet Dancey, Ontario Institute for Cancer Research
8:15 – 8:30 am	Introduction
8:30 – 8:50 am	Joseph Lehar, Novartis "A systematic approach towards anti-cancer drug combinations"

8:50 – 9:10 am	Helen Chen, NCI “Clinical – safety, efficacy and clinical indication/need”
9:10 – 9:30 am	Grant Williams, Williams Cancer Drug Consulting LLC “Regulatory issues”
9:30 – 9:50 am	Paul Smith, AstraZeneca “The AZ/Merck partnership”
9:50 – 10:20 am	<i>Coffee Break</i>
10:20 – 12:00pm	Roundtable discussion
12:00 – 1:45 pm	<i>Lunch</i>
2:00 – 4:30 pm	AFTERNOON SESSION: “Targeting Ras-driven tumors” Discussion Leader: Frank McCormick, UCSF, Helen Diller Family Comprehensive Cancer Center
2:00 – 2:15 pm	Introduction
2:15 – 2:55 pm	David Tuveson, Cambridge, UK “Malignant transformation of pancreatic cells and melanocytes”
2:55 – 3:15 pm	Discussion
3:15 – 3:55 pm	Dafna Bar-Sagi, NYU “Unexplored modalities of Ras-driven oncogenesis”
3:55 – 4:15 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: “Tumor cell hierarchy and drug responses” Discussion Leader: Jeff Settleman, Genentech
7:30 – 7:45 am	Introduction
7:45 – 8:25 am	Austin Gurney, Oncomed “Cancer stem cell fate with therapeutics targeting the Notch and Wnt pathways”
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Jeff Settleman, Genentech “Reversible tolerance to anti-cancer drugs”
9:25 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i>

TUESDAY JULY 12

7:30 – 8:15 am	<i>Breakfast</i>
8:15 – 12:00 pm	MORNING SESSION: “Signaling redundancy and chemoresistance” Discussion Leader: Jennifer Grandis, University of Pittsburgh
8:15 – 8:30 am	Introduction
8:30 – 9:10 am	Jeffrey Engelman, MGH “Resistance mechanisms to targeted therapies”
9:10 – 9:30 am	Discussion
9:30 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:40 am	Richard Marais, ICR “Translating BRAF and RAS biology into new therapies”
10:40 – 11:00 am	Discussion
11:00 – 11:40 am	Gordon Mills, MDACC “Overcoming challenges to personalized medicine”
11:40 – 12:00 pm	Discussion
12:00 – 1:45 pm	<i>Lunch</i>
2:00 – 4.30 pm	NETWORKING AFTERNOON TBD
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: “Targeting the tumor microenvironment” Discussion Leader: Lisa Coussens, UCSF
7:30 – 7:45 pm	Introduction
7:45 – 8:25 pm	Johanna Joyce, MSKCC “Tumor-infiltrating macrophages modulate cancer progression and the response to therapy”
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Gabriele Bergers, UCSF “Feedback control mechanisms of the microenvironment in tumor progression and resistance”
9:25 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i>

WEDNESDAY JULY 13

- 7:30 – 8:15 am *Breakfast*
- 8:15 – 11:00 am **MORNING SESSION: “Drugging the undruggable, thinking the unthinkable”**
Discussion Leader: Ed Sausville, University of Maryland
- 8:15 – 8:30 am Introduction
- 8:30 – 9:10 am Peter Vogt, The Scripps Research Institute, La Jolla
“Targeting Myc”
- 9:10 – 9:30 am Discussion
- 9:30 – 10:00 am *Coffee Break*
- 10:00 – 10:40 am Jeff Toretsky, Georgetown University
“Disordered proteins cause challenges but also open opportunities when targeting tumorigenic transcription”
- 10:40 – 11:00 am Discussion
- 11:00 – 12:00 pm **POSTER PRESENTATIONS – Four Selected Presenters**
- 12:00 – 1:45pm *Lunch*
- 2:00 – 5:45 pm **AFTERNOON SESSION: “Pericellular proteolysis revisited”**
Discussion Leader: Lynn Matrisian, Vanderbilt University
- 2:00 – 2:15 pm Introduction
- 2:15 – 2:55 pm Thomas Bugge, NIH
“Membrane-anchored serine proteases in epithelial carcinogenesis”
- 2:55 – 3:15 pm Discussion
- 3:15 – 3:45 pm *Coffee Break*
- 3:45 – 4:25 pm Dan Dransfield, Dyax Corp
“Antibodies as protease inhibitors - utilizing phage display to identify selective MMP inhibitors”
- 4:25 – 4:45 pm Discussion
- 4.45 – 5.25 Charles Craik, UCSF
“Imaging pericellular proteolysis in epithelial cancer”
- 5.25 – 5.45 Discussion
- 6:00 – 10:00 pm ***Farewell Banquet***

THURSDAY JULY 14

- 7:30 - 8:30 am *Breakfast*
CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

**Amgen
Bristol Meyers Squibb
Celgene
Genentech
Hoffman-La Roche
Johnson & Johnson
Novartis
Lilly
Merck
Pfizer**

MOLECULAR THERAPEUTICS OF CANCER 2012 CONFERENCE

Princeton University
July 15-19, 2012

Program Chair: Edward Sausville, University of Maryland